

# Caner SÃ¼sal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8388490/publications.pdf>

Version: 2024-02-01

135  
papers

5,017  
citations

101496

36  
h-index

102432

66  
g-index

135  
all docs

135  
docs citations

135  
times ranked

4312  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of Extended Right Lobe Liver Transplantations. <i>Liver Transplantation</i> , 2022, 28, 807-818.	1.3	6
2	Kidney Transplants from Elderly Donors: The Experience of a Reference Center in Croatia. <i>Experimental and Clinical Transplantation</i> , 2022, 20, 19-27.	0.2	0
3	Influence of Calcineurin Inhibitor Choice on Outcomes in Kidney Transplant Recipients Aged $\geq 60$ Y: A Collaborative Transplant Study Report. <i>Transplantation</i> , 2022, 106, e212-e218.	0.5	1
4	Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1024.e7-1024.e12.	2.8	15
5	Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk. <i>Pediatric Nephrology</i> , 2022, 37, 2503-2514.	0.9	8
6	The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation. <i>Nature Medicine</i> , 2022, 28, 989-998.	15.2	20
7	Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1739.	1.0	6
8	Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome. <i>Frontiers in Immunology</i> , 2022, 13, 829228.	2.2	8
9	Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients. <i>Kidney International</i> , 2022, 101, 639-642.	2.6	8
10	Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients. <i>Frontiers in Immunology</i> , 2022, 13, 840136.	2.2	15
11	Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1873-1883.	2.6	37
12	Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 98-106.	2.2	22
13	Heart transplantation across preformed donor-specific antibody barriers using a perioperative desensitization protocol. <i>American Journal of Transplantation</i> , 2022, 22, 2064-2076.	2.6	7
14	Impact of HLA compatibility in recipients of kidneys from expanded criteria donors: A Collaborative Transplant Study Report. <i>International Journal of Immunogenetics</i> , 2021, 48, 201-210.	0.8	12
15	Influence of cold ischemia time on the outcome of kidney transplants from donors aged 70 years and above. A Collaborative Transplant Study Report. <i>Transplantation</i> , 2021, Publish Ahead of Print, 2461-2469.	0.5	7
16	Can PIRCHE-II Matching Outmatch Traditional HLA Matching?. <i>Frontiers in Immunology</i> , 2021, 12, 631246.	2.2	14
17	Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients. <i>Pediatric Nephrology</i> , 2021, 36, 2473-2484.	0.9	16
18	Low Pre-Transplant Caveolin-1 Serum Concentrations Are Associated with Acute Cellular Tubulointerstitial Rejection in Kidney Transplantation. <i>Molecules</i> , 2021, 26, 2648.	1.7	1

#	ARTICLE	IF	CITATIONS
19	Higher CD19+CD25+ Bregs are independently associated with better graft function in renal transplant recipients. BMC Nephrology, 2021, 22, 180.	0.8	5
20	Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1073-1082.	2.2	88
21	Relationship of transitional regulatory B and regulatory T cells and immunosuppressive drug doses in stable renal transplant recipients. Immunity, Inflammation and Disease, 2021, 9, 1252-1271.	1.3	3
22	Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines, 2021, 9, 857.	2.1	49
23	Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2. Frontiers in Medicine, 2021, 8, 721286.	1.2	11
24	Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival. Frontiers in Immunology, 2021, 12, 724331.	2.2	4
25	Analysis of de novo donor-specific <sc>HLAâ€DPB1</sc> antibodies in kidney transplantation. Hla, 2021, 98, 423-430.	0.4	5
26	Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2. Kidney International, 2021, 100, 700-702.	2.6	22
27	Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. Vaccines, 2021, 9, 1130.	2.1	36
28	Maternal versus paternal living kidney transplant donation is associated with lower rejection in young pediatric recipients: A Collaborative Transplant Study report. Pediatric Transplantation, 2021, , e14154.	0.5	4
29	Kidney re-transplantation in a child across the barrier of persisting angiotensin II type I receptor antibodies. Pediatric Nephrology, 2021, 36, 725-729.	0.9	0
30	Rare Malignant Indications for Liver Transplantation: A Collaborative Transplant Study Report. Frontiers in Surgery, 2021, 8, 678392.	0.6	3
31	Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients. Transplant International, 2021, 35, 10071.	0.8	2
32	Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoabsorption. Frontiers in Medicine, 2021, 8, 781491.	1.2	3
33	Differential Influence of Donor Age Depending on the Indication for Liver Transplantationâ€A Collaborative Transplant Study Report. Transplantation, 2020, 104, 779-787.	0.5	19
34	Association of graft survival with tacrolimus exposure and late intraâ€patient tacrolimus variability in pediatric and young adult renal transplant recipientsâ€an international CTS registry analysis. Transplant International, 2020, 33, 1681-1692.	0.8	17
35	Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation. Frontiers in Immunology, 2020, 11, 1886.	2.2	8
36	Should kidney allografts from old donors be allocated only to old recipients?. Transplant International, 2020, 33, 849-857.	0.8	12

#	ARTICLE	IF	CITATIONS
37	The Differential Influence of Cold Ischemia Time on Outcome After Liver Transplantation for Different Indicationsâ€”Who Is at Risk? A Collaborative Transplant Study Report. <i>Frontiers in Immunology</i> , 2020, 11, 892.	2.2	35
38	Three is not enough. <i>Transplant International</i> , 2020, 33, 612-614.	0.8	1
39	Critical evaluation of a possible role of HLA epitope matching in kidney transplantation. <i>Transplantation Reviews</i> , 2020, 34, 100533.	1.2	21
40	Editorial: Transplantation of Marginal Organsâ€”Immunological Aspects and Therapeutic Perspectives. <i>Frontiers in Immunology</i> , 2020, 11, 612576.	2.2	2
41	Relevance of donorâ€”specific antibody monitoring after kidney transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center. <i>Hla</i> , 2019, 94, 11-15.	0.4	10
42	Outcomes and complications following ABOâ€”incompatible kidney transplantation performed after desensitization by semiâ€”selective immunoabsorption â€”a retrospective study. <i>Transplant International</i> , 2019, 32, 1286-1296.	0.8	18
43	Effectiveness of different immunoabsorption columns for anti-A/B antibody depletion. <i>Atherosclerosis Supplements</i> , 2019, 40, 68-72.	1.2	3
44	Progressive improvement in shortâ€”, mediumâ€”and longâ€”term graft survival in kidney transplantation patients in Ireland â€” a retrospective study. <i>Transplant International</i> , 2019, 32, 974-984.	0.8	12
45	Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report. <i>American Journal of Transplantation</i> , 2019, 19, 2805-2813.	2.6	32
46	Pulse Pressure and Outcome in Kidney Transplantation: Results From the Collaborative Transplant Study. <i>Transplantation</i> , 2019, 103, 772-780.	0.5	5
47	Clinical outcomes after ABO-incompatible renal transplantation. <i>Lancet, The</i> , 2019, 394, 1989.	6.3	1
48	Is Belatacept Switch Safe in Renal Transplant Recipients With Donor-specific Antibodies?. <i>Transplantation</i> , 2019, 103, 1984-1985.	0.5	0
49	Pretransplant Cancer in Kidney Recipients in Relation to Recurrent and De Novo Cancer Incidence Posttransplantation and Implications for Graft and Patient Survival. <i>Transplantation</i> , 2019, 103, 581-587.	0.5	20
50	Kidneys From Elderly Deceased Donorsâ€”Is 70 the New 60?. <i>Frontiers in Immunology</i> , 2019, 10, 2701.	2.2	23
51	Transplantation of Marginal Organs: Immunological Aspects and Therapeutic Perspectives in Kidney Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 3142.	2.2	20
52	Is There a Need for Additional DQ Matching?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 683-684.	2.2	4
53	Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1065-1072.	0.4	38
54	The possible critical role of T-cell help in DSA-mediated graft loss. <i>Transplant International</i> , 2018, 31, 577-584.	0.8	23

#	ARTICLE	IF	CITATIONS
55	Circulating and urinary microRNAs as possible biomarkers in kidney transplantation. <i>Transplantation Reviews</i> , 2018, 32, 110-118.	1.2	8
56	Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis. <i>United European Gastroenterology Journal</i> , 2018, 6, 255-262.	1.6	17
57	Influence of Blood Pressure and Calcineurin Inhibitors on Kidney Function After Heart or Liver Transplantation. <i>Transplantation</i> , 2018, 102, 845-852.	0.5	15
58	SP698OUTCOMES FOLLOWING LIVING DONOR KIDNEY TRANSPLANTATION IN PATIENTS WITH DONOR-SPECIFIC HLA ANTIBODIES AFTER DESENSITIZATION WITH IMMUNOADSORPTION. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i582-i582.	0.4	0
59	No Increase in Colon Cancer Risk Following Induction with Neu5Gc-Bearing Rabbit Anti-T Cell IgG (ATG) in Recipients of Kidney Transplants. <i>Cancers</i> , 2018, 10, 324.	1.7	10
60	SaO011A PHASE-I CLINICAL TRIAL OF DONOR-DERIVED MIC CELL INFUSION FOR THE INDUCTION OF DONOR-SPECIFIC HYPORESPONSIVENESS AFTER LIVING DONOR KIDNEY TRANSPLANTATION (TOL-1 STUDY). <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i320-i320.	0.4	0
61	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002572.	3.9	76
62	Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. <i>Kidney International</i> , 2018, 94, 964-973.	2.6	198
63	Split liver transplantation: Current developments. <i>World Journal of Gastroenterology</i> , 2018, 24, 5312-5321.	1.4	66
64	Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion â€” a Phase I Study (TOL-1). <i>Blood</i> , 2018, 132, 4539-4539.	0.6	0
65	Desensitization and survival in kidney transplant recipients. <i>Nature Reviews Nephrology</i> , 2017, 13, 196-198.	4.1	4
66	An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 799-807.	0.9	6
67	Increased risk of infection-associated death with incompatible kidney transplantations. <i>Transplant International</i> , 2017, 30, 1209-1211.	0.8	5
68	Results of a Patient Survey for Assessment Services in Renal Transplant Patients With a History of Cancer. <i>Progress in Transplantation</i> , 2017, 27, 365-368.	0.4	0
69	ABO-Incompatible Kidney Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 234.	2.2	73
70	Clinical Relevance of HLA Antibodies in Kidney Transplantation: Recent Data from the Heidelberg Transplant Center and the Collaborative Transplant Study. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	0.9	17
71	Pretransplant human leukocyte antigen antibodies detected by single-antigen bead assay are a risk factor for long-term kidney graft loss even in the absence of donor-specific antibodies. <i>Transplant International</i> , 2016, 29, 988-998.	0.8	11
72	Association of CD30 transcripts with Th1 responses and proinflammatory cytokines in patients with end-stage renal disease. <i>Human Immunology</i> , 2016, 77, 403-410.	1.2	1

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of antibody induction therapy in the current era of kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1730-1738.	0.4	32
74	Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1360-1367.	0.4	34
75	Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients. <i>Pediatric Nephrology</i> , 2016, 31, 1157-1166.	0.9	39
76	Donor-specific antibodies require preactivated immune system to harm renal transplant. <i>EBioMedicine</i> , 2016, 9, 366-371.	2.7	30
77	Virtual PRA replaces traditional PRA: small change but significantly more justice for sensitized patients. <i>Transplant International</i> , 2015, 28, 708-709.	0.8	5
78	Three-Year Outcomes Following 1420 ABO-Incompatible Living-Donor Kidney Transplants Performed After ABO Antibody Reduction. <i>Transplantation</i> , 2015, 99, 400-404.	0.5	130
79	Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. <i>Transplantation</i> , 2015, 99, 1976-1980.	0.5	75
80	Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoabsorption. <i>Transplantation</i> , 2015, 99, 2364-2371.	0.5	44
81	Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. <i>Journal of Dermatological Science</i> , 2015, 77, 37-45.	1.0	10
82	Clinical Relevance of HLA Antibody Monitoring after Kidney Transplantation. <i>Journal of Immunology Research</i> , 2014, 2014, 1-5.	0.9	42
83	HLA antibody screening in kidney transplantation: current guidelines. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 415-420.	0.8	6
84	ATG induction in renal transplant recipients: Long-term hazard of severe infection is associated with long-term functional T cell impairment but not the ATG-induced CD4 cell decline. <i>Human Immunology</i> , 2014, 75, 561-569.	1.2	11
85	The collaborative transplant study registry. <i>Transplantation Reviews</i> , 2013, 27, 43-45.	1.2	79
86	Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. <i>Atherosclerosis Supplements</i> , 2013, 14, 199-202.	1.2	23
87	Current pharmacotherapeutical options for the prevention of kidney transplant rejection. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1029-1041.	0.9	2
88	Current role of human leukocyte antigen matching in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 438-444.	0.8	104
89	Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. <i>Transplantation</i> , 2013, 95, 19-47.	0.5	679
90	Influence of Test Technique on Sensitization Status of Patients on the Kidney Transplant Waiting List. <i>American Journal of Transplantation</i> , 2013, 13, 2075-2082.	2.6	83

#	ARTICLE	IF	CITATIONS
91	Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients. <i>Transplant International</i> , 2013, 26, 331-338.	0.8	14
92	Role and Value of Luminex®-Detected HLA Antibodies before and after Kidney Transplantation. <i>Transfusion Medicine and Hemotherapy</i> , 2013, 40, 190-195.	0.7	25
93	Release of Soluble CD30 After Allogeneic Stimulation Is Mediated by Memory T Cells and Regulated by IFN- $\gamma$ and IL-2. <i>Transplantation</i> , 2013, 96, 154-161.	0.5	28
94	ABO-Incompatible Kidney Transplantation Enabled by Non-Antigen-Specific Immunoabsorption. <i>Transplantation</i> , 2012, 93, 827-834.	0.5	59
95	IVIg and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. <i>Transplant International</i> , 2012, 25, 1165-1173.	0.8	77
96	Posttransplant sCD30 as a biomarker to predict kidney graft outcome. <i>Clinica Chimica Acta</i> , 2012, 413, 1350-1353.	0.5	15
97	Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure. <i>Human Immunology</i> , 2012, 73, 1102-1108.	1.2	9
98	Impact of HLA Matching and HLA Antibodies in Organ Transplantation: A Collaborative Transplant Study View. <i>Methods in Molecular Biology</i> , 2012, 882, 267-277.	0.4	19
99	Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoabsorption and anti-CD20 therapy. <i>Transplant International</i> , 2012, 25, 506-517.	0.8	59
100	Prevention of antibody-mediated kidney transplant rejection. <i>Transplant International</i> , 2012, 25, 633-645.	0.8	24
101	Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft. <i>Transplant Immunology</i> , 2011, 25, 72-76.	0.6	10
102	No Association of Kidney Graft Loss With Human Leukocyte Antigen Antibodies Detected Exclusively by Sensitive Luminex Single-Antigen Testing: A Collaborative Transplant Study Report. <i>Transplantation</i> , 2011, 91, 883-887.	0.5	107
103	Posttransplant sCD30 as a Predictor of Kidney Graft Outcome. <i>Transplantation</i> , 2011, 91, 1364-1369.	0.5	39
104	Reply to Focosi and Boggi. <i>Transplantation</i> , 2011, 92, e15-e16.	0.5	1
105	Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch?. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 467-474.	0.8	7
106	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 560-572.	1.0	54
107	Does Borderline Kidney Allograft Rejection Always Require Treatment?. <i>Transplantation</i> , 2010, 90, 427-432.	0.5	14
108	An Integrative Approach for the Transplantation of High-Risk Sensitized Patients. <i>Transplantation</i> , 2010, 90, 645-653.	0.5	48

#	ARTICLE	IF	CITATIONS
109	Impact of HLA Compatibility on Lung Transplant Survival and Evidence for an HLA Restriction Phenomenon: A Collaborative Transplant Study Report. <i>Transplantation</i> , 2010, 90, 912-917.	0.5	31
110	Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. <i>Human Immunology</i> , 2009, 70, 627-630.	1.2	36
111	Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: A Collaborative Transplant Study report. <i>Human Immunology</i> , 2009, 70, 569-573.	1.2	83
112	HLA Antibodies and the Occurrence of Early Adverse Events in the Modern Era of Transplantation: A Collaborative Transplant Study Report. <i>Transplantation</i> , 2009, 87, 1367-1371.	0.5	40
113	Expression of Regulatory T-Cell-Related Molecule Genes and Clinical Outcome in Kidney Transplant Recipients. <i>Transplantation</i> , 2009, 87, 857-863.	0.5	37
114	Successful Treatment of Chronic Antibody-Mediated Rejection With IVIG and Rituximab in Pediatric Renal Transplant Recipients. <i>Transplantation</i> , 2008, 86, 1214-1221.	0.5	102
115	Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss. <i>Human Immunology</i> , 2007, 68, 652-660.	1.2	26
116	Antibodies against MICA Antigens and Kidney-Transplant Rejection. <i>New England Journal of Medicine</i> , 2007, 357, 1293-1300.	13.9	386
117	Serum sCD30 in Monitoring of Alloresponse in Well HLA-Matched Cadaveric Kidney Transplantations. <i>Transplantation</i> , 2005, 80, 1809-1812.	0.5	22
118	Evaluation of T-Cell Receptor Repertoires in Patients with Long-Term Renal Allograft Survival. <i>American Journal of Transplantation</i> , 2005, 5, 746-756.	2.6	21
119	Advances in pre- and posttransplant immunologic testing in kidney transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 29-34.	0.3	50
120	Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. <i>Human Immunology</i> , 2004, 65, 810-816.	1.2	32
121	SERIAL PERIPHERAL BLOOD INTERLEUKIN-18 AND PERFORIN GENE EXPRESSION MEASUREMENTS FOR PREDICTION OF ACUTE KIDNEY GRAFT REJECTION. <i>Transplantation</i> , 2004, 77, 1589-1595.	0.5	30
122	Serial Peripheral Blood Perforin and Granzyme B Gene Expression Measurements for Prediction of Acute Rejection in Kidney Graft Recipients. <i>American Journal of Transplantation</i> , 2003, 3, 1121-1127.	2.6	99
123	The effect of ATC on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. <i>Clinical Transplantation</i> , 2003, 17, 217-224.	0.8	21
124	Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. <i>International Immunopharmacology</i> , 2003, 3, 1791-1801.	1.7	48
125	Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection1. <i>Transplantation</i> , 2003, 75, 421-423.	0.5	81
126	Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. <i>Transplantation</i> , 2003, 76, 1231-1232.	0.5	44



#	ARTICLE	IF	CITATIONS
127	Identification of Highly Responsive Kidney Transplant Recipients Using Pretransplant Soluble CD30. Journal of the American Society of Nephrology: JASN, 2002, 13, 1650-1656.	3.0	140
128	SOLUBLE CD30 AS A PREDICTOR OF KIDNEY GRAFT OUTCOME1. Transplantation, 2002, 73, 3-6.	0.5	102
129	Kidney graft failure and presensitization against HLA Class I and Class II antigens1. Transplantation, 2002, 73, 1269-1273.	0.5	133
130	Induction of apoptosis in human lymphocytes by the herbicide 2,4-dichlorophenoxyacetic acid. Human Immunology, 2001, 62, 64-74.	1.2	44
131	Increased Soluble Fas in HIV-Infected Hemophilia Patients with CD4+and CD8+Cell Count Increases and Viral Load and Immune Complex Decreases. AIDS Research and Human Retroviruses, 2001, 17, 329-335.	0.5	6
132	Recognition of defined epitopes by affinity-purified anti-immunoglobulin Fab autoantibodies isolated from HIV-infected humans. , 1999, 12, 169-176.		5
133	Isotypes and IgG Subclasses of Antiâ€Fab Antibodies in Human Immunodeficiency Virusâ€Infected Hemophilia Patients. Vox Sanguinis, 1994, 66, 37-45.	0.7	17
134	CD4+ Lymphocyte Depletion in HIVâ€Infected Patients is Associated with gp120â€Immunoglobulinâ€Complement Attachment to CD4+ Cells. Vox Sanguinis, 1993, 64, 31-36.	0.7	21
135	Molecular Mimicry between HIVâ€1 and Antigen Receptor Molecules: A Clue to the Pathogenesis of AIDS. Vox Sanguinis, 1993, 65, 10-17.	0.7	54